Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.55 |
| ▸ | PAX8 | Q06710 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | P4HB | P07237 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23734429 | 0.89 | KMT2A (0.58) | KMT2APAX8ALDH1A1LMNAHSD11B1 | |
| SCHEMBL23480400 | 0.78 | KMT2A (0.69) | KMT2APAX8ALDH1A1LMNAHSD11B1 | |
| SCHEMBL14860981 | 0.76 | MAPK1 (0.48) | KMT2AALDH1A1LMNATSHRMAPK1 | |
| SCHEMBL1696190 | 0.75 | NPC1 (0.47) | KMT2AALDH1A1MAPK1MAPTNPC1 | |
| SCHEMBL25002673 | 0.75 | KMT2A (0.65) | KMT2APAX8ALDH1A1LMNAHSD11B1 | |
| SCHEMBL29275318 | 0.73 | HSD11B1 (0.78) | KMT2APAX8ALDH1A1LMNAHSD11B1 | |
| SCHEMBL12237280 | 0.73 | ALDH1A1 (0.44) | KMT2APAX8ALDH1A1LMNAHSD17B10 | |
| SCHEMBL23983125 | 0.73 | SMN1; SMN2 (0.50) | KMT2AALDH1A1LMNATSHRMAPK1 | |
| SCHEMBL17993598 | 0.73 | CYP2C19 (0.43) | KMT2AALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL4393639 | 0.72 | TSHR (0.45) | KMT2AALDH1A1LMNATSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | INTOCELL, INC. (KR) | 2023-11-07 | — | — | US | disclosed |
| US-11084801-B2 | Benzodiazepine derivatives and uses thereof | INTOCELL, INC. (KR) | 2021-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | GABRB3, GABRB2, GABRB1 | KMT2A 1869/4885PAX8 2812/4885ALDH1A1 900/4885 |
| US-11084801-B2 | Benzodiazepine derivatives and uses thereof | GABRB3, GABRB2, GABRB1 | KMT2A 1869/4885PAX8 2812/4885ALDH1A1 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.